You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Myeloablative Autologous Gene Editing

Showing 51 - 75 of 9,686
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency Trial in Paris (ARTEGENE drug product)

Not yet recruiting
  • Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
  • ARTEGENE drug product
  • Paris, France
    Department of Pediatric Immunology, Hematology and Rheumatology
Sep 26, 2022

Sickle Cell Disease Trial in Memphis (Plerixafor)

Recruiting
  • Sickle Cell Disease
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 11, 2023

Beta Thalassaemia Trial in Milan (Safety and Efficacy assessments)

Active, not recruiting
  • Beta Thalassaemia
  • Safety and Efficacy assessments
  • Milan, Italy
    Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR
Nov 22, 2022

Sickle Cell Disease Trial in United States (bb1111)

Recruiting
  • Sickle Cell Disease
  • bb1111
  • Birmingham, Alabama
  • +8 more
Jul 15, 2022

Lysosomal Storage Disease, Metachromatic Leukodystrophy Trial in Milan (OTL-200 Gene Therapy)

Active, not recruiting
  • Lysosomal Storage Disease
  • Metachromatic Leukodystrophy
  • OTL-200 Gene Therapy
  • Milan, Italy
    Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR
Nov 4, 2022

ImplementingNational Biobank of PD With WGS and Functional

Not yet recruiting
  • Parkinson Disease
  • REM Sleep Behavior Disorder
  • whole genome sequencing
  • Pozzilli, Italy
    IRCCS Neuromed
Feb 13, 2023

Gaucher Disease, Type 3 Trial (Gene therapy, Enzyme Replacement Agent)

Not yet recruiting
  • Gaucher Disease, Type 3
  • Gene therapy
  • Enzyme Replacement Agent
  • (no location specified)
Apr 14, 2023

HIV-1 Infections Trial in Washington (HAART, T cells)

Completed
  • HIV-1 Infections
  • Washington, District of Columbia
    Walter Reed Army Medical Center
Aug 17, 2022

Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects Trial in Shanghai (Signal Switch

Recruiting
  • Advanced Gynecologic Tumors
  • +3 more
  • Signal Switch Receptor Modified TIL
  • Shanghai, Shanghai, China
    Shanghai Tenth People's Hospital
Dec 20, 2022

Adenosine Deaminase Deficiency, Severe Combined Immunodeficiencies (SCID) Trial in London (genetic, other, drug)

Completed
Has Results
  • Adenosine Deaminase Deficiency
  • Severe Combined Immunodeficiencies (SCID)
  • Infusion of autologous EFS-ADA LV CD34+ cells
  • +3 more
  • London, United Kingdom
    Great Ormond Street Hospital for Children NHS Foundation Trust
Aug 20, 2021

Multiple Myeloma Trial in United States (procedure, drug, behavioral)

Completed
Has Results
  • Multiple Myeloma
  • One Autologous Transplant
  • +5 more
  • Birmingham, Alabama
  • +35 more
Oct 19, 2021

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Gastric Cancer, Colorectal Cancer, Pancreatic Cancer Trial in Pittsburgh (Tumor Infiltrating Lymphocytes (TIL), Fludarabine +

Recruiting
  • Gastric Cancer
  • +9 more
  • Tumor Infiltrating Lymphocytes (TIL)
  • Fludarabine + Cyclophosphamide combination
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 21, 2022

Uveal Tumors, Melanoma, Uveal Trial in Pittsburgh (Tumor Infiltrating Lymphocytes (TIL))

Recruiting
  • Uveal Neoplasms
  • Melanoma, Uveal
  • Tumor Infiltrating Lymphocytes (TIL)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 21, 2022

Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)

Not yet recruiting
  • Malignant Epithelial Neoplasms
  • TCR-transduced T cells
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Apr 22, 2022

Tumor Infiltrating Lymphocytes Trial (Autologous tumor-infiltrating lymphocytes)

Not yet recruiting
  • Tumor Infiltrating Lymphocytes
  • Autologous tumor-infiltrating lymphocytes
  • (no location specified)
Nov 28, 2021

ß-thalassemia Trial in Shanghai (BD211)

Not yet recruiting
  • β-thalassemia
  • BD211
  • Shanghai, China
    Shanghai Ruijin Hospital
Mar 16, 2023

ß-thalassemia Trial (BD211)

Not yet recruiting
  • β-thalassemia
  • BD211
  • (no location specified)
Mar 15, 2023

Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Dresden, Heidelberg (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
  • Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
  • Gemtuzumab Ozogamicin
  • Dresden, Germany
  • +1 more
Dec 20, 2022

Adenosine Deaminase Severe Combined Immune Deficiency Trial (A cryopreserved formulation of autologous mPB CD34+ hematopoietic

Not yet recruiting
  • Adenosine Deaminase Severe Combined Immune Deficiency
  • A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
  • (no location specified)
Jun 20, 2022

AIDS-related Lymphoma, HIV Trial in Hamburg (PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC))

Terminated
  • AIDS-related Lymphoma
  • HIV Infections
  • PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)
  • Hamburg, Germany
    University Medical Center Hamburg-Eppendorf
Sep 4, 2022

Cerebral Adrenoleukodystrophy (CALD) Trial in Worldwide (Lenti-D Drug Product (eli-cel))

Completed
Has Results
  • Cerebral Adrenoleukodystrophy (CALD)
  • Lenti-D Drug Product (eli-cel)
  • Los Angeles, California
  • +7 more
Mar 25, 2022

HIV Trial in Cincinnati (SB-728-T, Expanded unmodified autologous CD4+ T cells)

Active, not recruiting
  • HIV Infections
  • SB-728-T
  • Expanded unmodified autologous CD4+ T cells
  • Cincinnati, Ohio
    University of Cincinnati
Jan 1, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in La Jolla (Autologous hematopoietic stem cell transplantation,

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Autologous hematopoietic stem cell transplantation
  • +2 more
  • La Jolla, California
    Scripps Green Hospital
Aug 16, 2022

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa Trial in Redwood City, Worcester (EB-101)

Active, not recruiting
  • Epidermolysis Bullosa
  • Recessive Dystrophic Epidermolysis Bullosa
  • EB-101
  • Redwood City, California
  • +1 more
Apr 5, 2022